These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28379361)

  • 21. Specific Antibody Deficiencies in Clinical Practice.
    Sorensen RU; Edgar D
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):801-808. PubMed ID: 30682575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Critical View of Specific Antibody Deficiencies.
    Sorensen RU
    Front Immunol; 2019; 10():986. PubMed ID: 31118939
    [No Abstract]   [Full Text] [Related]  

  • 23. Mucosal and systemic immunization with pneumococcal polysaccharide type 3, 4 and 14 in the rat.
    van den Dobbelsteen GP; Brunekreef K; Sminia T; van Rees EP
    Adv Exp Med Biol; 1995; 371B():1605-10. PubMed ID: 7502866
    [No Abstract]   [Full Text] [Related]  

  • 24. Pneumococcal polysaccharide immunization in infants and children.
    Cowan MJ; Ammann AJ; Wara DW; Howie VM; Schultz L; Doyle N; Kaplan M
    Pediatrics; 1978 Nov; 62(5):721-7. PubMed ID: 31592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies.
    Choi EH; Zhang F; Lu YJ; Malley R
    Clin Vaccine Immunol; 2016 Feb; 23(2):162-7. PubMed ID: 26677201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of allohaemagglutinins in the diagnosis of a polysaccharide antibody deficiency.
    Schaballie H; Vermeulen F; Verbinnen B; Frans G; Vermeulen E; Proesmans M; De Vreese K; Emonds MP; De Boeck K; Moens L; Picard C; Bossuyt X; Meyts I
    Clin Exp Immunol; 2015 May; 180(2):271-9. PubMed ID: 25516411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections.
    Sanders LA; Rijkers GT; Kuis W; Tenbergen-Meekes AJ; de Graeff-Meeder BR; Hiemstra I; Zegers BJ
    J Allergy Clin Immunol; 1993 Jan; 91(1 Pt 1):110-9. PubMed ID: 8423268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the immune response to pneumococcal capsular polysaccharides.
    Jeurissen A; Boudewijns M; Proesmans M; Ceuppens JL; De Boeck K; Bossuyt X
    Acta Clin Belg; 2003; 58(2):106-10. PubMed ID: 12836493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal assessment of the ability of children with recurrent respiratory tract infections to produce anti-polysaccharide antibodies.
    Tuerlinckx D; Vermeulen F; Pékus V; de Bilderling G; Glupczynski Y; Collet S; Jamart J; Bodart E; Mascart F
    Clin Exp Immunol; 2007 Aug; 149(2):295-302. PubMed ID: 17511778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?
    Musher DM; Watson DA; Baughn RE
    J Infect Dis; 1990 Apr; 161(4):736-40. PubMed ID: 2319167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies against pneumococcal C-polysaccharide are not protective.
    Nielsen SV; Sørensen UB; Henrichsen J
    Microb Pathog; 1993 Apr; 14(4):299-305. PubMed ID: 8326853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK.
    Hazlewood M; Nusrat R; Kumararatne DS; Goodall M; Raykundalia C; Wang DG; Joyce HJ; Milford-Ward A; Forte M; Pahor A
    Clin Exp Immunol; 1993 Aug; 93(2):157-64. PubMed ID: 8348740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Using Different Response Criteria for Pneumococcal Polysaccharide Vaccination for Assessment of Humoral Immune Status.
    Hoffman TW; van Kessel DA; Rijkers GT
    J Clin Immunol; 2018 Feb; 38(2):149-152. PubMed ID: 29247371
    [No Abstract]   [Full Text] [Related]  

  • 34. Antipolysaccharide antibodies in 450 children with otitis media.
    Misbah SA; Griffiths H; Mitchell T; Freeland A; Haeney MR; Chapel HM
    Clin Exp Immunol; 1997 Jul; 109(1):67-72. PubMed ID: 9218826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulatory role of intravenous gammaglobulin (IgIV) on the in vitro antibody response to a pneumococcal polysaccharide antigen.
    Leiva LE; Monjure H; Sorensen RU
    J Clin Immunol; 2015 Feb; 35(2):206-12. PubMed ID: 25504423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.
    Blanchard-Rohner G; Pollard AJ
    Expert Rev Vaccines; 2011 May; 10(5):673-84. PubMed ID: 21604987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment and clinical interpretation of polysaccharide antibody responses.
    Paris K; Sorensen RU
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):462-4. PubMed ID: 18051217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Use of Salmonella Typhim Vaccine to Diagnose Antibody Deficiency.
    Bausch-Jurken MT; Verbsky JW; Gonzaga KA; Elms NP; Hintermeyer MK; Gauld SB; Routes JM
    J Clin Immunol; 2017 Jul; 37(5):427-433. PubMed ID: 28589420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease.
    Emmadi M; Khan N; Lykke L; Reppe K; G Parameswarappa S; Lisboa MP; Wienhold SM; Witzenrath M; Pereira CL; Seeberger PH
    J Am Chem Soc; 2017 Oct; 139(41):14783-14791. PubMed ID: 28945368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.